Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Clinical Trials

Set Alert for Clinical Trials

Positive Data Backs Inivata's T790 Test For Use in Non-Biopsy Lung Cancer Patients

Positive data from a recently published study has backed the use of Inivata's liquid biopsy platform for detecting T790 mutations in lung cancer patients unable to undergo tissue biopsies.

Cancer In Vitro Diagnostics StartUps and SMEs

Latest From Clinical Trials

Starts & Stops: ICS' Emblok Medtronic's Arctic Front, Abbott's Absorb, Boston Scientific's S-ICD

Starts & Stops is a regular feature highlighting Medtech Insight editors' picks of noteworthy medtech clinical trial initiations, completions and suspensions each month. Over the last month, 31 new trials started, 25 trial were completed, one trial was "reinitiated," and six trials were terminated or suspended, according to meddevicetracker.

Clinical Trials Research & Development

Japan’s New 'Fast-Break Scheme' To Reduce Clinical Trial Burden For Medtech

Japan’s “fast-break scheme” is coming soon and will be the country’s fourth procedure for accelerating the approval of important medical devices.

Approvals Clinical Trials

Device Debuts: Tryton, Myriad Genetics, Integra Lifesciences, Acelity, And Toyota

This edition of device debuts highlights a wide variety of innovative devices introduced into commercial markets since the beginning of March, including a new stent for side-branch coronary interventions, an assay that identifies which breast-cancer patients do not need chemotherapy, a full ankle prosthesis, improvements to a negative-pressure wound therapy system, and a robotic system that helps paralyzed people learn to walk again.

Research & Development Clinical Trials

Game On For Akili's Cognitive Control Tech

A digital video game developed by Akili Interactive Labs for treating cognitive disorders has demonstrated in a pilot study its ability to improve cognitive control test scores of neurotypical children and children with sensory processing dysfunction (SPD). The company is also anticipating a market launch of the device for pediatric attention deficit hyperactivity disorder in 2018.

Digital Health Neurology

Clinical Data Double-Boost Supports Medtronic's HeartWare Investment

Results of the LATERAL trial presented at the recent ISHLT conference show Medtronic's HVAD can be implanted safely through a thoracotomy procedure instead of the standard sternotomy approach, which is far more invasive. At the same meeting, subset data from the ENDURANCE trial confirms that the sickest heart-failure patients treated with HVAD have similar outcomes as less sick patients, and results of the ENDURANCE Supplement show that blood pressure management minimizes the risk of stroke with HVAD.

Cardiology Cardiovascular

Abbott To Restrict Absorb To Registries In Europe For At Least A Year

A letter to Abbott's customers states that the company will restrict its Absorb bioresorbable stent to registries in Europe while it investigates possible safety issues flagged in clinical trials.

Clinical Trials Commercial

'All-Comers' Trial Finds Increased Risk Of Thrombosis With Abbott's Absorb BVS Stent

Preliminary two-year results from the randomized AIDA trial comparing Abbott's Absorb GT1 BVS and Abbott's Xience Prime drug-eluting stent found patients treated with Absorb were almost four times as likely to develop a stent thrombosis. The results are the latest in disappointing clinical news for the bioabsorbable scaffold.

Research & Development Innovation

MDxHealth Prostate Cancer Test Identifies Increased Risk of Cancer Recurrence

MDxHealth has released results from a prospective study demonstrating biomarkers from its Confirm MDx prostate cancer test identifies men at increased risk of prostate cancer recurrence. The test could help urologists monitor therapy response to improve the personalized treatment of castration resistant prostate cancer (CRPC).

Cancer In Vitro Diagnostics

ACC 2017: Disappointing Absorb Results Blamed On Implant Approach

Two-year results of the ABSORB III trial, comparing Abbott's Absorb bioresorbable stent to its Xience metal drug-eluting stent, showed a higher risk of target vessel failure with Absorb, prompting the US FDA to send-out a "Dear Doctor" letter reiterating the importance of following the recommended implantation technique.

Clinical Trials Research & Development
See All